Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com


The Global Cellular Health Screening Market is Predict to reach $4.3 Billion by 2028, at a CAGR of 9%

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Cellular Health Screening Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Cellular Health Screening Market size is expected to reach $4.3 billion by 2028, rising at a market growth of 9.0% CAGR during the forecast period.

The Blood market is leading the Global Cellular Health Screening Market by Sample Type in 2021; thereby, achieving a market value of $2.0 billion by 2028. The frequent usage of blood samples by medical professionals as well as the use of diagnostic kits for assessing various illness conditions, organ function, and potential risk analysis are driving this segment's expansion. The introduction of new diagnostic tools that utilize blood for screening and detection is also promoting the collection of blood samples for diagnosis.

The Hospital market acquired the maximum revenue share in the Global Cellular Health Screening Market by Collection Site in 2021; thereby, achieving a market value of $1.8 billion by 2028. Hospitals serve as the principal location for diagnosis and treatment for the majority of the population. One of the key elements influencings is the usage of diagnostic products for all inpatients and outpatients for health screening.

The Multi-test Panels market is showcasing a CAGR of 10.8% during (2022 - 2028). The use of such panels for screening numerous biomarkers in a single run has produced many benefits, including improved diagnostic skills, greater accuracy, and lower costs in healthcare settings. For patients at risk for hereditary breast cancer, a multi test panel delivers a higher diagnostic yield.

The North America market dominated the Global Cellular Health Screening Market by Region in 2021; thereby, achieving a market value of $1.6 billion by 2028. The Asia Pacific market is experiencing a CAGR of 9.7% during (2022 - 2028). Additionally, The Europe market would exhibit a CAGR of 8.7% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/cellular-health-screening-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Quest Diagnostics Incorporated, OPKO Health, Inc., Laboratory Corporation of America Holdings, Genova Diagnostics, Telomere Diagnostics, Inc., Life Length, S.L., Repeat Diagnostics, Inc., SpectraCell Laboratories, Inc. (Beingmate Group Co. Ltd.), Cell Science Systems Corp. and Segterra, Inc.

Global Cellular Health Screening Market Segmentation

By Sample Type

  • Blood
  • Saliva
  • Serum
  • Urine

By Collection Site

  • Hospital
  • Diagnostic Labs
  • Home
  • Office

By Test Type

  • Single Test Panels
    • Oxidative Stress Tests
    • Inflammation Tests
    • Telomere Tests
    • Heavy Metals Tests
  • Multi-test Panels

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Quest Diagnostics Incorporated
  • OPKO Health, Inc.
  • Laboratory Corporation of America Holdings
  • Genova Diagnostics
  • Telomere Diagnostics, Inc.
  • Life Length, S.L.
  • Repeat Diagnostics, Inc.
  • SpectraCell Laboratories, Inc. (Beingmate Group Co. Ltd.)
  • Cell Science Systems Corp.
  • Segterra, Inc.

Related Reports:



SUBSCRIPTION MODEL